Modulo Bio

Modulo Bio is a private, preclinical-stage biotech founded in 2021 and based in San Francisco. The company is pioneering a novel approach to neurodegenerative diseases by targeting the neuroimmune system, specifically the function of microglia. Its integrated platform utilizes human stem cell-derived models and advanced computational analytics to discover drug targets and candidates that can enhance microglia-mediated neuroprotection. Modulo is positioned to address a massive unmet medical need in neurology by developing first-in-class small molecule therapeutics.

Integrated platform combining human stem cell-derived neuroimmune models (microglia, neurons, astrocytes), multiomics profiling, CRISPR perturbation, and machine learning to identify targets and drugs that reprogram microglia into neuroprotective states.

Modulo operates in the competitive neuroimmunology space, facing rivals ranging from large pharma (e.g., Biogen, Genentech) to biotechs (e.g., Alector, Vigil Neuroscience) also targeting microglia and neuroinflammation. Its differentiation lies in its proprietary integration of human stem cell models and machine learning for discovery.